Photo by cdc from unsplash
High titers of cold agglutinins jeopardize the quality of an apheresis product meant for autologous or allogeneic transplant. Management of transplant patients with cold agglutinin disease (CAD) is often experience‐based… Click to show full abstract
High titers of cold agglutinins jeopardize the quality of an apheresis product meant for autologous or allogeneic transplant. Management of transplant patients with cold agglutinin disease (CAD) is often experience‐based and under reported, yet decisions must be made quickly to optimize product management and patient outcomes. There remains a lack of data quantifying cell recovery and viability when using various warming methodologies.
Keywords:
cell;
agglutinin disease;
warm hpc;
viability;
cold agglutinin
Journal Title: Transfusion
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Transfusion
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!